On January 8, Eastern Time, Moderna options saw a total of 122203 contracts traded, with calls accounting for 59% and puts making up 40%.
Moderna has 1074467 contracts outstanding, with calls accounting for 56% and puts making up 43%.
The top volume gainer was the 33 dollars Call option expiring on January 9, 2026, with 4185 contracts traded.
On the news front, Based on recent key news:

1. Jan 7, UBS downgraded Moderna to neutral from buy, citing concerns over flat revenues and profitability challenges. UBS cut its price target to $34, indicating a potential downside. This downgrade contributed to the stock's decline. Source: MarketWatch

2. Jan 7, Bayer filed a lawsuit against Moderna, alleging patent infringement related to mRNA technology. This legal action added uncertainty and pressure on Moderna's stock. Source: MT Newswires

3. Jan 7, Analysts highlighted the binary outcome of upcoming trial results, with potential significant stock movement. UBS noted the stakes are high, with a 60% to 65% probability of success. This uncertainty affected investor sentiment. Source: MarketWatchBiotech sector faces revenue challenges.
Please note: The chart below does not include options expiring within five days.
<img src="https://assets.lbctrl.com/h5hub/optrank/images/2026-01-09/ST_US_MRNA_en.png" alt="image" original-src="https://assets.lbctrl.com/h5hub/optrank/images/2026-01-09/ST_US_MRNA_en.png"/>

MRNA

On January 8, Eastern Time, Moderna options saw a total of 122203 contracts traded, with calls accounting for 59% and puts making up 40%.

Trending | MRNA Plummets 5% on Thursday, Some Put options Soar 350%